Hemangeol propranolol: Additional Phase II/III data

Additional data from 276 patients with infantile hemangiomas in the intent-to-treat (ITT) population of a double-blind, international Phase II/III trial showed that 3 mg/kg daily Hemangeol for 6 months met

Read the full 302 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE